CLYM
Financials
- Market Capitalization 758.13 M
- Employee 29
- Founded 2018
- CEO N/A
- Website www.climbbio.com
- Headquarter Delaware, United States
- FIGI BBG00ZNKL0K6
- Industry Biotechnology
Related tickers
| # | Name | Price | 24h % | 7d % | 1M % | 1Y % | Market Cap | Last 7 Days | |
|---|---|---|---|---|---|---|---|---|---|
| 2631 |  ZVRA Zevra Therapeutics, Inc. - Common Stock | 13.06 USD | -0.91% | -9.56% | +1.95% | +22.74% | 772.04 M USD | ||
| 2635 |  OMER Omeros Corporation - Common Stock | 10.50 USD | +4.90% | +1.65% | +19.05% | +165.15% | 759.94 M USD | ||
| 2637 |  RIGL Rigel Pharmaceuticals, Inc. - Common Stock | 41.21 USD | -0.22% | -3.17% | +23.98% | +36.77% | 762.47 M USD | ||
| 2649 |  SPRY ARS Pharmaceuticals, Inc. - Common Stock | 7.61 USD | -1.68% | -7.08% | -22.74% | -17.37% | 755.70 M USD |
Frequently asked questions about Climb Bio, Inc. - Common Stock
What is the Climb Bio, Inc. - Common Stock stock price today?
The current price of Climb Bio, Inc. - Common Stock (CLYM) is 13.24. Over the past 24 hours, the stock has changed by +0.23%. Follow the CLYM chart for real-time price dynamics.
What is the stock ticker of Climb Bio, Inc. - Common Stock?
Climb Bio, Inc. - Common Stock trades under the ticker CLYM. Tickers can differ by exchange, so always check the exchange and instrument details before trading.
Is Climb Bio, Inc. - Common Stock stock going up?
CLYM has changed by -1.34% over the last week, +13.55% over the last month, and +142.05% over the last year. Review the chart to see whether the current move is part of a broader trend.
What was Climb Bio, Inc. - Common Stock net income for the last quarter?
Climb Bio, Inc. - Common Stock reported net income of -13.72 M for the last quarter. The previous quarter showed -17.52 M, which means net income changed by +21.66%.
How many employees does Climb Bio, Inc. - Common Stock have?
As of the latest available data, Climb Bio, Inc. - Common Stock has 29 employees. Workforce size can provide additional context about the company's scale and operations.
What is Climb Bio, Inc. - Common Stock EBITDA?
Climb Bio, Inc. - Common Stock EBITDA is -15.2 M, and its EBITDA margin is 60.79 K%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.
How can I buy Climb Bio, Inc. - Common Stock stock?
You can buy Climb Bio, Inc. - Common Stock (CLYM) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.
Should I invest in Climb Bio, Inc. - Common Stock stock?
Investing in Climb Bio, Inc. - Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the CLYM chart and related analysis on metatrader.com as part of your research.